Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Hepatology Reports
Published in: Current Hepatology Reports 3/2020

01-09-2020 | Hepatitis B | Hepatitis B (JK Lim, Section Editor)

Prevention and Management of HBV in Organ Transplantation

Authors: Stela Celaj, Josh Levitsky

Published in: Current Hepatology Reports | Issue 3/2020

Login to get access

Abstract

Purpose of Review

Hepatitis B (HBV) infection and reactivation have a significant impact on solid organ transplantation. This review summarizes past significant studies and new findings in the field, and presents the latest recommendations for HBV management in solid organ transplant population.

Recent Findings

Significant advances in antiviral therapy have resulted in improved graft outcomes and have notably reduced the need for prophylaxis with hepatitis B immunoglobin. Emerging treatment avenues such as immunotherapies and small molecules inhibitors are being developed with the intent of eradicating HBV infection.

Summary

Substantial suppression of HBV is obtained with the current antiviral prophylaxis in transplant patients. This has allowed for safely expanding the donor pool to HBcAb-positive grafts with good outcomes. Novel therapies are showing a promising future for achieving functional cure for HBV.
Literature
1.
2.
Ward JW, Hinman AR. What is needed to eliminate hepatitis B virus and hepatitis C virus as global health threats. Gastroenterology. 2019;156:297–310.PubMed
3.
Giovanna F, Bortolotti F, Francesco D. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48:335–52.
4.
Ayoub WS, Martin P, Bhamidimarri KR. Hepatitis B virus infection and organ transplantation. Gastroenterol Hepatol (N Y). 2018;14:33.
5.
Ji M, Hu K. Recent advances in the study of hepatitis B virus covalently closed circular DNA. Virol Sin. 2017;32:454–64.PubMedPubMedCentral
6.
Nam H, Nilles KM, Levitsky J, Ison MG (2018) Donor-derived viral infections in liver transplantation. Transplantation 102:1824–1836.
7.
8.
Huprikar S, Danziger-Isakov L, Ahn J, Naugler S, Blumberg E, Avery RK, et al. Solid organ transplantation from hepatitis B virus-positive donors: consensus guidelines for recipient management. Am J Transplant. 2015;15:1162–72.PubMed
9.
Feuerhake A, Muller R, Lauchart W, Pichlmayr R, Schmidt FW. HBV-vaccination in recipients of kidney allografts. Vaccine. 1984;2:255–6.PubMed
10.
Carey W, Pimentel R, Westveer MK, Vogt D, Broughan T. Failure of hepatitis B immunization in liver transplant recipients: results of a prospective trial. Am J Gastroenterol. 1990;85:1590–2.PubMed
11.
Marzano A, Gaia S, Ghisetti V, Carenzi S, Premoli A, Debernardi-Venon W, et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transplant. 2005;11:402–9.
12.
13.
Domínguez M. Vaccination against hepatitis B virus in cirrhotic patients on liver transplant waiting list. Liver Transplant. 2000;6:440–2.
14.
Villeneuve E, Vincelette J, Villeneuve JP Ineffectiveness of hepatitis B vaccination in cirrhotic patients waiting for liver transplantation. Can J Gastroenterol 14 Suppl B:59B-62B.
15.
•• Te H, Doucette K (2019) Viral hepatitis: guidelines by the American Society of Transplantation Infectious Disease Community of Practice. Clin transplant. https://​doi.​org/​10.​1111/​ctr.​13514Important review issued by a major specialty society with current recommendations regarding the management of HBV and other hepatitides in the transplant population.
16.
Engler SH, Sauer PW, Golling M, Klar EA, Benz C, Stremmel W, et al. Immunogenicity of two accelerated hepatitis B vaccination protocols in liver transplant candidates. Eur J Gastroenterol Hepatol. 2001;13:363–7.PubMed
17.
Arslan M, Wiesner RH, Sievers C, Egan K, Zein NN. Double-dose accelerated hepatitis B vaccine in patients with end-stage liver disease. Liver Transplant. 2001;7:314–20.
18.
•• Danziger-Isakov L, Kumar D (2019) Vaccination of solid organ transplant candidates and recipients: guidelines from the American society of transplantation infectious diseases community of practice. Clin transplant. https://​doi.​org/​10.​1111/​ctr.​13563. Important guidelines issued by a major specialty society providing clinicians guidance on vaccination policies in transplant population.
19.
Schillie S, Harris A, Link-Gelles R, Romero J, Ward J, Nelson N. Recommendations of the advisory committee on immunization practices for use of a hepatitis B vaccine with a novel adjuvant. MMWR Morb Mortal Wkly Rep. 2018;67:455–8.PubMedPubMedCentral
20.
Féray C, Zignego AL, Samue D, Bismuth A, Reynes M, Tiollais P, et al. Persistent hepatitis B virus infection of mononuclear blood cells without concomitant liver infection: the liver transplantation model. Transplantation. 1990;49:1155–8.PubMed
21.
Todo S, Demetris AJ, van Thiel D, Teperman L, Fung JJ, Starzl TE. Orthotopic liver transplantation for patients with hepatitis B virus–related liver disease. Hepatology. 1991;13:619–26.PubMedPubMedCentral
22.
Angus PW, Locarnini SA, McCaughan GW, Jones RM, McMillan JS, Bowden DS. Hepatitis B virus precore mutant infection is associated with severe recurrent disease after liver transplantation. Hepatology. 1995;21:14–8.PubMed
23.
Chauhan R, Lingala S, Gadiparthi C, Lahiri N, Mohanty SR, Wu J, et al. Reactivation of hepatitis B after liver transplantation: current knowledge, molecular mechanisms and implications in management. World J Hepatol. 2018;10:352–70.PubMedPubMedCentral
24.
Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou J-P, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med. 1993;329:1842–7.PubMed
25.
Papatheodoridis GV, Sevastianos V, Burroughs AK. Prevention of and treatment for hepatitis B virus infection after liver transplantation in the nucleoside analogues era. Am J Transplant. 2003;3:250–8.PubMed
26.
Sherman M, Yurdaydin C, Sollano J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. YGAST. 2006;130:2039–49.
27.
Gish RG, Lok AS, Chang TT, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology. 2007;133:1437–44.PubMed
28.
Sherman M, Yurdaydin C, Simsek H, Silva M, Liaw YF, Rustgi VK, et al. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology. 2008;48:99–108.PubMed
29.
Chang T-T, Lai C-L, Kew Yoon S, Lee SS, Coelho HSM, Carrilho FJ, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2010;51:422–30.PubMed
30.
Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381:468–75.PubMed
31.
Cholongitas E, Papatheodoridis GV. High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis B virus recurrence after liver transplantation: a systematic review. Am J Transplant. 2013;13:353–62.PubMed
32.
Buganza-Torio E, Doucette KE. Management of viral hepatitis in solid organ transplant recipients. Infect Dis Clin N Am. 2018;32:635–50.
33.
Sripongpun P, Mannalithara A, Kwo PY, Kim WR. Potential benefits of switching liver transplant recipients to tenofovir alafenamide prophylaxis. Clin Gastroenterol Hepatol. 2020;18:747–9.PubMed
34.
Chen G, Liu H, Hu ZQ, Bai JH, Liu QY, Zhao YP, et al. A new scheme with infusion of hepatitis B immunoglobulin combined with entecavir for prophylaxis of hepatitis B virus recurrence among liver transplant recipients. Eur J Gastroenterol Hepatol. 2015;27:901–6.PubMed
35.
Radhakrishnan K, Chi A, Quan DJ, Roberts JP, Terrault NA. Short course of postoperative hepatitis B immunoglobulin plus antivirals prevents reinfection of liver transplant recipients. Transplantation. 2017;101:2079–82.PubMed
36.
•• Fung J, Wong T, Chok K, et al (2017) Long-term outcomes of entecavir monotherapy for chronic hepatitis B after liver transplantation: results up to 8 years. Hepatology 66:1036–1044 One of the longest cohort studies up-to-date demonstrating success of entecavir monotherapy with no HBIG prophylaxis.
37.
Takaki A, Yagi T, Yamamoto K. Safe and cost-effective control of post-transplantation recurrence of hepatitis B. Hepatol Res. 2015;45:38–47.PubMed
38.
Coffin CS, Stock PG, Dove LM, Berg CL, Nissen NN, Curry MP, et al. Virologic and clinical outcomes of hepatitis B virus infection in HIV-HBV coinfected transplant recipients. Am J Transplant. 2010;10:1268–75.PubMedPubMedCentral
39.
Lee EC, Kim SH, Lee SD, Park H, Lee S-A, Park S-J. High-dose hepatitis B immunoglobulin therapy in hepatocellular carcinoma with hepatitis B virus-DNA/hepatitis B e antigen-positive patients after living donor liver transplantation. World J Gastroenterol. 2016;22:3803–12.PubMedPubMedCentral
40.
Couto CA, Bittencourt PL, Farias AQ, Lallee MP, Cançado ELR, Massarollo PCB, et al. Human polyclonal anti-hepatitis B surface antigen immunoglobulin reduces the frequency of acute rejection after liver transplantation for chronic hepatitis B. Rev Inst Med Trop Sao Paulo. 2001;43:335–7.PubMed
41.
Wong SY, Levitsky J. Chronic rejection related to hepatitis B immunoglobulin discontinuation in a liver transplant recipient. Transpl Int. 2011;24:104–6.
42.
•• Terrault NA, Lok ASF, McMahon BJ, Chang K-M, Hwang JP, Jonas MM, Brown RS, Bzowej NH, Wong JB (2018) Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Clin liver Dis 12:33–34. Important review issued by a major specialty society with current recommendations regarding the diagnosis and management of HBV.
43.
Cholongitas E. Review of the pharmacological management of hepatitis B viral infection before and after liver transplantation. World J Gastroenterol. 2013;19:9189–97.PubMedPubMedCentral
44.
Angelico M, Nardi A, Marianelli T, Caccamo L, Romagnoli R, Tisone G, et al. Hepatitis B-core antibody positive donors in liver transplantation and their impact on graft survival: evidence from the Liver Match cohort study. J Hepatol. 2013;58:715–23.PubMed
45.
Cholongitas E, Papatheodoridis GV, Burroughs AK. Liver grafts from anti-hepatitis B core positive donors: a systematic review. J Hepatol. 2010;52:272–9.PubMed
46.
Skagen CL, Jou JH, Said A. Risk of de novo hepatitis in liver recipients from hepatitis-B core antibody-positive grafts—a systematic analysis. Clin Transpl. 2011;25:E243–9.
47.
Saab S, Waterman B, Chi AC, Tong MJ (2010) Comparison of different immunoprophylaxis regimens after liver transplantation with hepatitis B core antibody positive donors: a systematic review. Liver transplant 16:NA-NA.
48.
Vizzini G, Gruttadauria S, Volpes R, D’Antoni A, Pietrosi G, Filì D, et al. Lamivudine monoprophylaxis for de novo HBV infection in HBsAg-negative recipients with HBcAb-positive liver grafts. Clin Transpl. 2011;25:E77–81.
49.
Bohorquez HE, Cohen AJ, Girgrah N, Bruce DS, Carmody IC, Joshi S, et al. Liver transplantation in hepatitis B core-negative recipients using livers from hepatitis B core-positive donors: a 13-year experience. Liver Transplant. 2013;19:611–8.
50.
Chang MS, Olsen SK, Pichardo EM, Stiles JB, Rosenthal-Cogan L, Brubaker WD, et al. Prevention of de novo hepatitis B in recipients of core antibody-positive livers with lamivudine and other nucleos(t)ides. Transp J. 2013;95:960–5.
51.
Wright AJ, Fishman JA, Chung RT. Lamivudine compared with newer antivirals for prophylaxis of hepatitis B core antibody positive livers: a cost-effectiveness analysis. Am J Transplant. 2014;14:629–34.PubMed
52.
Abdelmalek MF, Pasha TM, Zein NN, Persing DH, Wiesner RH, Douglas DD. Subclinical reactivation of hepatitis B virus in liver transplant recipients with past exposure. Liver Transplant. 2003;9:1253–7.
53.
Loggi E, Micco L, Ercolani G, Cucchetti A, Bihl FK, Grazi GL, et al. Liver transplantation from hepatitis B surface antigen positive donors: a safe way to expand the donor pool. J Hepatol. 2012;56:579–85.PubMed
54.
Li Z, Hu Z, Xiang J, Zhou J, Yan S, Wu J, et al. Use of hepatitis B surface antigen-positive grafts in liver transplantation: a matched analysis of the US national database. Liver Transplant. 2014;20:35–45.
55.
Fabrizio F, Bunnapradist S, Martin P. Transplanting kidneys from donors with prior hepatitis B infection: one response to the organ shortage. J Nephrol. 2002;15:605–13.PubMed
56.
Lee J, Cho JH, Lee JS, et al. Pretransplant hepatitis B viral infection increases risk of death after kidney transplantation. Med (United States). 2016;95:e3671.
57.
Mahboobi N, Tabatabaei SV, Blum HE, Alavian SM. Renal grafts from anti-hepatitis B core-positive donors: a quantitative review of the literature. Transpl Infect Dis. 2012;14:445–51.PubMed
58.
De Feo TM, Grossi P, Poli F, et al. Kidney transplantation from anti-HBc+ donors: results from a retrospective Italian study. Transplantation. 2006;81:76–80.PubMed
59.
Madayag RM, Johnson LB, Bartlett ST, Schweitzer EJ, Constantine NT, McCarter RJ, Kuo PC, Keay S, Oldach DW (1997) Use of renal allografts from donors positive for hepatitis B core antibody confers minimal risk for subsequent development of clinical hepatitis B virus disease. In: Transplantation. pp 1781–1786.
60.
Chancharoenthana W, Townamchai N, Pongpirul K, Kittiskulnam P, Leelahavanichkul A, Avihingsanon Y, et al. The outcomes of kidney transplantation in hepatitis B surface antigen (HBsAg)-negative recipients receiving graft from HBsAg-positive donors: a retrospective, propensity score-matched study. Am J Transplant. 2014;14:2814–20.PubMed
61.
Tuncer M, Tekin S, Yücetin L, Şengül A, Demirbaş A (2012) Hepatitis B surface antigen positivity is not a contraindication for living kidney donation. In: Transplant. Proc. pp 1628–1629.
62.
Dhillon GS, Levitt J, Mallidi H, Valentine VG, Gupta MR, Sista R, et al. Impact of hepatitis B core antibody positive donors in lung and heart-lung transplantation: an analysis of the united network for organ sharing database. Transplantation. 2009;88:842–6.PubMed
63.
Manickam P, Krishnamoorthi R, Kanaan Z, Gunasekaran PK, Cappell MS. Prognostic implications of recipient or donor hepatitis B seropositivity in thoracic transplantation: analysis of 426 hepatitis B surface antigen-positive recipients. Transpl Infect Dis. 2014;16:597–604.PubMed
64.
Hartwig MG, Patel V, Palmer SM, Cantu E, Appel JZ, Messier RH, Davis RD (2005) Hepatitis B core antibody positive donors as a safe and effective therapeutic option to increase available organs for lung transplantation. Transplantation 80:320–325.
65.
Shitrit ABG, Kramer MR, Bakal I, Morali G, Ari Z Ben, Shitrit D (2006) Lamivudine prophylaxis for hepatitis B virus infection after lung transplantation. Ann Thorac Surg 81:1851–1852.
66.
Chen YC, Chuang MK, Chou NK, et al. Twenty-four year single-center experience of hepatitis B virus infection in heart transplantation. In: Transplant. Proc: Elsevier; 2012. p. 910–2.
67.
Wang SS, Chou NK, Ko WJ, et al. Heart transplantation using donors positive for hepatitis. In: Transplant. Proc: Elsevier; 2004. p. 2371–3.
68.
Gish RG, Given BD, Lai CL, Locarnini SA, Lau JYN, Lewis DL, et al. Chronic hepatitis B: virology, natural history, current management and a glimpse at future opportunities. Antivir Res. 2015;121:47–58.PubMed
69.
Durantel D. New treatments to reach functional cure: virological approaches. Best Pract Res Clin Gastroenterol. 2017;31:329–36.PubMed
70.
Martinez MG, Villeret F, Testoni B, Zoulim F. Can we cure hepatitis B virus with novel direct-acting antivirals? Liver Int. 2020;40:27–34.PubMed
71.
Lopatin U. Drugs in the pipeline for HBV. Clin Liver Dis. 2019;23:535–55.PubMed
72.
Gill US, Battisti A, Kennedy PTF. Emerging tools in the changing landscape of chronic hepatitis B management. Expert Rev Anti-Infect Ther. 2019;17:943–55.PubMed
73.
Wedemeyer H, Schöneweis K, Bogomolov PO, Voronkova N, Chulanov V, Stepanova T, et al. Final results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of myrcludex B in cwith PEG-interferon alpha 2a in patients with chronic HBV/HDV co-infection. J Hepatol. 2019;70:e81.
74.
75.
Smolders EJ, Burger DM, Feld JJ, Kiser JJ. Review article: clinical pharmacology of current and investigational hepatitis B virus therapies. Aliment Pharmacol Ther. 2020;51:231–43.PubMed
76.
• Yuen MF, Agarwal K, Gane EJ, et al (2020) Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial. Lancet Gastroenterol Hepatol 5:152–166. A promising intial study that showed dose-dependent decreases in serum HBV DNA and RNA with a well tolerated HBV core inhibitior in CHB.
77.
Yuen MF, Gane EJ, Kim DJ, et al (2019) Antiviral activity, safety, and pharmacokinetics of capsid assembly modulator NVR 3-778 in patients with chronic HBV infection. Gastroenterology 156:1392-1403.e7.
78.
Yuen M-F, Locarnini S, Lim TH, STRASSER S, Sievert W, Cheng W, et al. Short term RNA interference therapy in chronic hepatitis B using JNJ-3989 brings majority of patients to HBsAg < 100 IU/ml threshold. J Hepatol. 2019;70:e51–2.
79.
Ramanan V, Shlomai A, Cox DBT, Schwartz RE, Michailidis E, Bhatta A, et al. CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus. Sci Rep. 2015;5:1–9.
80.
Schurich A, Pallett LJ, Jajbhay D, Wijngaarden J, Otano I, Gill US, et al. Distinct metabolic requirements of exhausted and functional virus-specific CD8 T cells in the same host. Cell Rep. 2016;16:1243–52.PubMedPubMedCentral
81.
Martinet J, Dufeu-Duchesne T, Bruder Costa J, Larrat S, Marlu A, Leroy V, Plumas J, Aspord C (2012) Altered functions of plasmacytoid dendritic cells and reduced cytolytic activity of natural killer cells in patients with chronic HBV infection. Gastroenterology 143:1586-1596.e8.
82.
83.
Schurich A, Khanna P, Lopes AR, Han KJ, Peppa D, Micco L, et al. Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-prone CD8 T cells in persistent hepatitis B virus infection. Hepatology. 2011;53:1494–503.PubMed
84.
85.
Chen Z, Cheng Y, Xu Y, Liao J, Zhang X, Hu Y, et al. Expression profiles and function of toll-like receptors 2 and 4 in peripheral blood mononuclear cells of chronic hepatitis B patients. Clin Immunol. 2008;128:400–8.PubMed
86.
•• Boni C, Vecchi A, Rossi M, et al (2018) TLR7 agonist increases responses of hepatitis B virus–specific T cells and natural killer cells in patients with chronic hepatitis B yreated with nucleos(T)Ide analogues. Gastroenterology 154:1764–1777.e7. One of the few clinical trials reporting efficacy of a TLR agonist stimulating immune responses in patients with CHB.
87.
Gane E, Zhao Y, Tan SK, Lau AH, Gaggar A, Subramanian M et al Efficacy and safety of oral TLR8 agonist Selgantolimod in virally suppressed adult patients with chronic hepatitis B: a phase 2, randomized, double-blind, placebo-controlled, Multicenter Study http://​www.​natap.​org/​2019/​AASLD/​AASLD_​79.​htm. Accessed 1 Mar 2020.
88.
Meng Z, Chen Y, Lu M. Advances in targeting the innate and adaptive immune systems to cure chronic hepatitis B virus infection. Front Immunol. 2020;10:3127.PubMedPubMedCentral
89.
•• Al Mahtab M, Akbar SMF, Aguilar JC, Guillen G, Penton E, Tuero A, Yoshida O, Hiasa Y, Onji M (2018) Treatment of chronic hepatitis B naïve patients with a therapeutic vaccine containing HBs and HBc antigens (a randomized, open and treatment controlled phase III clinical trial). PLoS One 13:e0201236. An important study that demostrated a safe and effective therapeutic vaccination as treatment potential for HBV.
90.
Aguilar J, Lobaina Y, Muzio V, García D, Pentón E, Iglesias E, et al. Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigen. Immunol Cell Biol. 2004;82:539–46.PubMed
91.
92.
Kruse RL, Shum T, Tashiro H, Barzi M, Yi Z, Whitten-Bauer C, et al. HBsAg-redirected T cells exhibit antiviral activity in HBV-infected human liver chimeric mice. Cytotherapy. 2018;20:697–705.PubMedPubMedCentral
Metadata
Title
Prevention and Management of HBV in Organ Transplantation
Authors
Stela Celaj
Josh Levitsky
Publication date
01-09-2020
Publisher
Springer US
Published in
Current Hepatology Reports / Issue 3/2020
Electronic ISSN: 2195-9595
DOI
https://doi.org/10.1007/s11901-020-00537-7

Other articles of this Issue 3/2020

Current Hepatology Reports 3/2020 Go to the issue

Hepatitis B (JK Lim, Section Editor)

Targeting Viral cccDNA for Cure of Chronic Hepatitis B

Fatty Liver Disease (V Ajmera, Section Editor)

Metabolic Targets in Nonalcoholic Steatohepatitis: Treating the Disease at the Metabolic Root

Portal Hypertension (J Gonzalez-Abraldes and E Tsochatzis, Section Editors)

Esophageal Varices: Primary Prophylaxis and Prevention and Management of Rebleeding

Fatty Liver Disease (V Ajmera, Section Editor)

Cardiovascular Disease in Nonalcoholic Steatohepatitis: Screening and Management

Portal Hypertension (J Gonzalez-Abraldes and E Tsochatzis, Section Editors)

Non-selective Beta-Blockers in Decompensated Cirrhosis

Portal Hypertension (J Gonzalez-Abraldes and E Tsochatzis, Section Editors)

Portal Hypertensive Ascites: Current Status
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits